Update on JAK2 inhibitors in myeloproliferative neoplasm

Therapeutic Advances in Hematology

Volumn 2, Issue 2, 2011, Pages 61-71

  Chan, Daniel ^a   Koren Michowitz, Maya ^b  

^a NATIONAL UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

JAK2 inhibitors; JAK2V617F; myeloproliferative neoplasm

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BMS 911543; C REACTIVE PROTEIN; ERLOTINIB; GANDOTINIB; GIVINOSTAT; HYDROXYUREA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; LENALIDOMIDE; LESTAURTINIB; LS 104; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NS 018; NS 108; PACRITINIB; PANOBINOSTAT; PEGINTERFERON; POMALIDOMIDE; RUXOLITINIB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WP 1066; XL 019;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ADVANCED CANCER; ALLELE; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; BLAST TRANSFORMATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; GENE MUTATION; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; LEUKOCYTOSIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOMA; MYELOFIBROSIS; MYELOID LEUKEMIA; MYELOID METAPLASIA; MYELOMONOCYTIC LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; POLYCYTHEMIA VERA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; REVIEW; SPLENOMEGALY; SYMPTOM ASSESSMENT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS;

EID: 84993810398     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711401646     Document Type: Review

References (80)

1. Apostolidou E. Kantarjian H.M. Verstovsek S. (2009) JAK2 inhibitors: A reality? A hope? Clin Lymphoma Myelomaitalic 9(Suppl. 3): S340–S345.
2. Barosi G. Birgegard G. Finazzi G. Griesshammer M. Harrison C. Hasselbalch H.C. et al. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113: 4829–4833.
3. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
4. Begna K.H. Mesa R.A. Pardanani A. Hogan W.J. Litzow M.R. McClure R.F. et al. (2010) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25: 301–304.
5. Carbuccia N. Murati A. Trouplin V. Brecqueville M. Adelaide J. Rey J. et al. (2009) Mutations of ASXL 1 gene in myeloproliferative neoplasms. Leukemia 23: 2183–2186.
6. Cervantes F. Dupriez B. Pereira A. Passamonti F. Reilly J.T. Morra E. et al. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113: 2895–2901.
7. Chen E. Beer P.A. Godfrey A.L. Ortmann C.A. Li J. Costa-Pereira A.P. et al. (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT 1 signaling. Cancer Cell 18: 524–535.
8. Chim C.S. Ma S.K. (2005) Eosinophilic leukemic transformation in polycythemia rubra vera (PRV). Leuk Lymphoma 46: 447–450.
9. Dawson M.A. Bannister A.J. Gottgens B. Foster S.D. Bartke T. Green A.R. et al. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461: 819–822.
10. Delhommeau F. Dupont S. Della Valle V. James C. Trannoy S. Masse A. et al. (2009) Mutation in TET 2 in myeloid cancers. N Engl J Med 360: 2289–2301.
11. Delhommeau F. Dupont S. Tonetti C. Masse A. Godin I. Le Couedic J.P. et al. (2007) Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109: 71–77.
12. Dupont S. Masse A. James C. Teyssandier I. Lecluse Y. Larbret F. et al. (2007) The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110: 1013–1021.
13. Ernst T. Chase A.J. Score J. Hidalgo-Curtis C.E. Bryant C. Jones A.V. et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH 2 in myeloid disorders. Nat Genet 42 (8): 722–726.
14. Ferrajoli A. Faderl S. Van Q. Koch P. Harris D. Liu Z. et al. (2007) WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67: 11291–11299.
15. Fiskus W. Manepalli R. Balusu R. (2010) Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F. Blood 116: 798–808.
16. Ghoreschi K. Laurence A. O'Shea J.J. (2009) Janus kinases in immune cell signaling. Immunol Rev 228: 273–287.
17. Goh K. Ong W. Hu C. (2007) SB1518: a potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders. Blood 110: 538–548.
18. Grand F.H. Hidalgo-Curtis C.E. Ernst T. Zoi K. Zoi C. McGuire C. et al. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182–6192.
19. Guardiola P. Anderson J.E. Bandini G. Cervantes F. Runde V. Arcese W. et al. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93: 2831–2838.
20. Guerini V. Barbui V. Spinelli O. Salvi A. Dellacasa C. Carobbio A. et al. (2008) The histone deacetylase inhibitor ITF 2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22: 740–747.
21. Hexner E.O. Serdikoff C. Jan M. Swider C.R. Robinson C. Yang S. et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663–5671.
22. Ho C.L. Lasho T.L. Butterfield J.H. Tefferi A. (2007) Global cytokine analysis in myeloproliferative disorders. Leuk Res 31: 1389–1392.
23. Horiguchi A. Asano T. Kuroda K. Sato A. Asakuma J. Ito K. et al. (2010) STAT 3 inhibitor WP 1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 102: 1592–1599.
24. Hultdin M. Sundstrom G. Wahlin A. Lundstrom B. Samuelsson J. Birgegard G. et al. (2007) Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol 24: 63–70.
25. Jabbour E. Kantarjian H. Cortes J. Thomas D. Garcia-Manero G. Ferrajoli A. et al. (2007) PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 110: 2012–2018.
26. Jager R. Gisslinger H. Berg T. (2009) Deletions of the transcription factor Ikaros in myeloproliferative neoplasms at transformation to acute myeloid leukemia. Blood 114: 435–445.
27. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
28. Jamieson C.H. Gotlib J. Durocher J.A. Chao M.P. Mariappan M.R. Lay M. et al. (2006) The JAK2V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 103: 6224–6229.
29. Kiladjian J.J. Cassinat B. Turlure P. Cambier N. Roussel M. Bellucci S. et al. (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108: 2037–2040.
30. Kralovics R. Passamonti F. Buser A.S. Teo S.S. Tiedt R. Passweg J.R. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
31. Kralovics R. Teo S.S. Li S. Theocharides A. Buser A.S. Tichelli A. et al. (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108: 1377–1380.
32. Langer C. Lengfelder E. Thiele J. Kvasnicka H.M. Pahl H.L. Beneke H. et al. (2005) Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 90: 1333–1338.
33. Levine R.L. Gilliland D.G. (2008) Myeloproliferative disorders. Blood 112: 2190–2198.
34. Levine R.L. Pardanani A. Tefferi A. Gilliland D.G. (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7: 673–683.
35. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
36. Li Z. Xu M. Xing S. Ho W.T. Ishii T. Li Q. et al. (2007) Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 282: 3428–3432.
37. Lipka D.B. Hoffmann L.S. Heidel F. Markova B. Blum M.C. Breitenbuecher F. et al. (2008) LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 7: 1176–1184.
38. Ma L. Zhao B. Walgren R. (2010) Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2V617F-Induced Hematologic Malignancy Models. Blood 116: 4087–4187.
39. Malinge S. Ben-Abdelali R. Settegrana C. Radford-Weiss I. Debre M. Beldjord K. et al. (2007) Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 109: 2202–2204.
40. Manshouri T. Quintas-Cardama A. Nussenzveig R.H. Gaikwad A. Estrov Z. Prchal J. et al. (2008) The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 99: 1265–1273.
41. Mercher T. Wernig G. Moore S.A. Levine R.L. Gu T.L. Frohling S. et al. (2006) JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108: 2770–2779.
42. Mesa R.A. Li C.Y. Ketterling R.P. Schroeder G.S. Knudson R.A. Tefferi A. (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105: 973–977.
43. Moliterno A. Roboz G. Carroll M. (2008) An open-label study of CEP-701 in patients with JAK2V617F-positive polycythemia vera and essential thrombocytosis. Blood 112: 99–109.
44. Nakaya Y. Naito H. Homan J. (2010) Preferential inhibition of an activated form of Janus Kinase 2 (JAK2) by a novel JAK2 inhibitor, NS-018. Blood 116: 4107–4117.
45. Napper A. (2008) Drug discovery and development of innovative therapeutics–IBC's 13th Annual World Congress. Approaches to cancer therapy. IDrugs 11: 705–709.
46. Noor S.J. Tan W. Wilding G.E. Ford L.A. Barcos M. Sait S.N. et al. (2010) Myeloid blastic transformation of myeloproliferative neoplasms-A review of 112 cases. Leuk Res in press.
47. Nussenzveig R.H. Swierczek S.I. Jelinek J. Gaikwad A. Liu E. Verstovsek S. et al. (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35: 32–38.
48. Oh S.T. Simonds E.F. Jones C. Hale M.B. Goltsev Y. Gibbs K.D. Jr. et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116: 988–992.
49. Paquette R. Sokol L. Shah N. (2008) A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood 112: 2810–2820.
50. Pardanani A. George G. Lasho T. (2010 a) A phase I / II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 116: 460–470.
51. Pardanani A. Gotlib J.R. Jamieson C. Cortes J.E. Talpaz M. Stone R.M. et al. (2011) Safety and efficacy of Tg101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol.
52. Pardanani A. Hood J. Lasho T. Levine R.L. Martin M.B. Noronha G. et al. (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21: 1658–1668.
53. Pardanani A. Lasho T. Smith G. Burns C.J. Fantino E. Tefferi A. (2009) CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23: 1441–1445.
54. Pardanani A. Lasho T.L. Finke C.M. Mai M. McClure R.F. Tefferi A. (2010 b) IDH 1 and IDH 2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24: 1146–1151.
55. Pardanani A.D. Levine R.L. Lasho T. Pikman Y. Mesa R.A. Wadleigh M. et al. (2006) MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108: 3472–3476.
56. Pikman Y. Lee B.H. Mercher T. McDowell E. Ebert B.L. Gozo M. et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270–e270.
57. Purandare A. Pardanani A. McDevitt T. (2010) Characterization of BMS-911543, a functionally selective small molecule inhibitor of JAK2. Blood 116: 4112–4122.
58. Quintas-Cardama A. Kantarjian H. Manshouri T. Luthra R. Estrov Z. Pierce S. et al. (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27: 5418–5424.
59. Rambaldi A. Dellacassa C. Finazzi G. Carobbio A. Ferrari M.L. Guglielmelli P. et al. (2010) A pilot study of the histone-deacetylase inhibitor givinostat in patients with Jak2v617f positive chronic myeloproliferative neoplasms. Br J Haematol 150: 446–455.
60. Ravandi F. Foran J. Verstovsek S. (2007) A phase I trial of AT9283, a mutlitargeted kinase inhibitor, in patients with refractory hematological malignancies. Blood 110: 904–914.
61. Santos F.P. Kantarjian H.M. Jain N. Manshouri T. Thomas D.A. Garcia-Manero G. et al. (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera / essential thrombocythemia myelofibrosis. Blood 115: 1131–1136.
62. Schindler C. Levy D.E. Decker T. (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282: 20059–20063.
63. Scott L.M. Tong W. Levine R.L. Scott M.A. Beer P.A. Stratton M.R. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.
64. Shannon K. van Etten R.A. (2005) JAKing up hematopoietic proliferation. Cancer Cell 7: 291–293.
65. Shide K. Nakaya Y. Kameda T. (2010) NS-018, a potent novel JAK2 inhibitor, effectively treats murine MPN induced by the Janus Kinase 2 (JAK2) V617F mutant. Blood 116: 4106–4116.
66. Tefferi A. (2008) Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 83: 491–497.
67. Tefferi A. Barosi G. Mesa R.A. Cervantes F. Deeg H.J. Reilly J.T. et al. (2006 b) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108: 1497–1503.
68. Tefferi A. Cortes J. Verstovsek S. Mesa R.A. Thomas D. Lasho T.L. et al. (2006 a) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108: 1158–1164.
69. Tefferi A. Lasho T.L. Abdel-Wahab O. Guglielmelli P. Patel J. Caramazza D. et al. (2010) IDH 1 and IDH 2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24: 1302–1309.
70. Vannucchi A.M. (2009) How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis. Leuk Res 33: 1581–1583.
71. Verstovsek S. (2009) Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia / polycythemia vera myelofibrosis. Blood 114: 3905–3915.
72. Verstovsek S. Deeg H. Odenike O. (2010 a) Phase 1 / 2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood 116: 2830–2831.
73. Verstovsek S. Kantarjian H. Mesa R.A. Pardanani A.D. Cortes-Franco J. Thomas D.A. et al. (2010 b) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127.
74. Verstovsek S. Manshouri T. Quintas-Cardama A. Harris D. Cortes J. Giles F.J. et al. (2008) WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2V617F mutation. Clin Cancer Res 14: 788–796.
75. Verstovsek S. Passamonti F. Rambaldi A. (2010 c) Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood 116: 313–323.
76. Verstovsek S. Tefferi A. Korblau S. (2007) Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera / essential thrombocythemia myelofibrosis. Blood 110: 3543–3553.
77. Wang Y. Fiskus W. Chong D.G. Buckley K.M. Natarajan K. Rao R. et al. (2009) Cotreatment with panobinostat and JAK2 inhibitor TG 101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114: 5024–5033.
78. Wang Y.L. Vandris K. Jones A. Cross N.C. Christos P. Adriano F. et al. (2008) JAK2 mutations are present in all cases of polycythemia vera. Leukemia 22: 1289–1299.
79. Wernig G. Kharas M.G. Okabe R. Moore S.A. Leeman D.S. Cullen D.E. et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13: 311–320.
80. Yamaoka K. Saharinen P. Pesu M. Holt V.E. III Silvennoinen O. O'Shea J.J. (2004) The Janus kinases (Jaks). Genome Biol 5: 253–263.